News

News Articles

Bluejay Therapeutics Announces the Appointment of Nancy Shulman, M.D., as Chief Medical Officer

SAN MATEO, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private biopharmaceutical company focused on the development of innovative cures for infectious diseases, today announced that Nancy Shulman, M.D., joined Bluejay as chief medical officer, bringing over 20 years of clinical development experience with her to Bluejay Therapeutics.

“Nancy is an experienced infectious disease clinician and expert clinical drug developer with successful track record in drug development including antivirals in both large pharmaceutical companies and startup biotech companies, and I am pleased to welcome her to the executive team,” said Keting Chu, M.D., Ph.D., founder and chief executive officer of Bluejay. “We will undoubtedly benefit from her prior experience leading the strategy and execution of both clinical research and clinical development across AbbVie’s infectious disease portfolio, as well as her experience advancing antivirals at Genentech/Roche.”

Prior to Bluejay, Dr. Shulman worked at Roche, Genentech, AbbVie, and most recently at Ambys Medicines, where she was the vice president of translational medicine. She brings broad clinical development experience ranging from first-in-human and translational studies through Phase 4 studies, including extensive experience in the virology/hepatology disease area, but also in immunology and oncology. She has been a part of multiple INDs and was a key leader on the NDA approvals of the HCV antivirals Viekira Pak®, Viekirax®, and Mavyret®.

Prior to joining industry, Nancy was an NIH-funded clinical/translational HIV researcher at Stanford University and was on the faculty in the Division of Infectious Diseases. She holds a B.A. in Biochemistry with a minor in Chinese from the University of Texas at Austin and an M.D. from the University of Kansas. She completed her residency in internal medicine and pediatrics at the University of Chicago and her infectious disease fellowship at Stanford.

Dr. Shulman added, “I have dedicated a significant part of my career to the treatment of infectious diseases, working on numerous agents for chronic viral infections, as well as evaluating a number of strategic pipeline expansion opportunities for large biotech and pharma. I was excited to learn of the HBV therapeutics being developed at Bluejay with first- or best-in-class therapeutic potential, and I am eager to bring effective treatments to the patients in need.”

Dr. Shulman joins a seasoned executive leadership team, including:
  • Hassan Javanbakht, Ph.D., chief scientific officer, was previously at Hoffman La-Roche, Gilead sciences and SQZ biotechnologies where he worked on developing novel antivirals and immunomodulators to treat HIV, HBV, influenza and other infectious diseases. He was part of the team that advanced Elipida® (RO4970335), a potent and highly selective NNRTI, into clinical development . He led the teams that developed a first-in-class small-molecule viral expression inhibitor (RG7834) and a liver-targeted anti-HBV locked nucleic acid (RG6004). His work also led to discovery of PAPD5/7 as host factors for HBV expression. He has authored more than 45 peer-reviewed scientific publications in high-impact journals and holds more than 11 issued patents and applications.
  • Kevin Lin, M.D., vice president of development, has over 30 years of experience in the biotechnology industry in the areas of process development, technology transfer, scale up, troubleshooting, GMP manufacturing, and CMC regulatory submission. He has worked at several biotech companies, such as Bayer Healthcare, Catalant, Avid Bioservices, ImmunityBio, and Kindred Biosciences.
  • Jeff Zablocki, Ph.D., vice president of chemistry, has led chemistry teams at AbbVie, Gilead, CV Therapeutics, Amgen, and Searle. Dr. Zablocki has discovered 15 development compounds including 3 approved agents: Lexiscan™ – an adenosine A2A agonist used in over 60 million patients as a pharmacological stress agent capturing a large market share; Ranexa™ for stable angina; and Voxilaprevir™ for Hepatitis C where he helped address pre-clinical metabolism challenges by applying novel medicinal chemistry approaches.
Read Full Article

BlueJay Therapeutics to Present at the 2nd Global IR@JPM Conference

SAN MATEO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- BlueJay Therapeutics, a private biopharmaceutical company focused on cures for infectious diseases, today announced that chairman and chief executive officer, Dr. Keting Chu, M.D., Ph.D., will present at the 2nd Global IR@JPM Conference on Thursday, January 20, 2022 in the biotech track to be held 7:30 - 9:30 p.m. ET.

Dr. Chu will provide an overview of the company, including BlueJay’s two therapeutic approaches with potential high rate of functional cure for HBV infections -- its best-in-class anti-HBsAg monoclonal antibody approach and novel, first-in-class HBsAg inhibitor program -- its preeminent management team with a proven track record in anti-infectives, strong patent position and backing by top healthcare investors.

To access the live webcast, please visit https://www.eventbrite.com/e/2022-global-ir-jpm-virtual-demo-day-tickets-220953005387.   

Read Full Article
2022 Global IR

2022 Global IR @ JPM Virtual Demo Day Tickets, Wed, Jan 19, 2022 at 7:00 PM | Eventbrite

Bluejay Therapeutics will present in the 2nd annual Global IR @ JPM (Jan. 19-20 EST).

Bluejay Therapeutics' presentation would be delivered live, via Zoom, as part of our Day 2 Global Biotech track (7:30-9:30 p.m. EST on Jan. 20).

Since 1993, BioCentury Inc. has been internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures.    Register

Lonza and BlueJay Therapeutics Announce Manufacturing Agreement for its Antibody BJT-778 Targeting Chronic HBV Infection

Basel, Switzerland, 17 November 2021 - BlueJay, a developer of innovative therapeutics for functional cures of chronic hepatitis B virus (HBV) infection, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, have entered a manufacturing agreement for BJT-778, one of BlueJay's lead candidates. This monoclonal antibody (mAb), targeting the HBV surface antigen (HBsAg), is currently under preclinical development for the restoration of patient's adaptive immunity and functional cure for chronic HBV infection.    Read Full Article

BLUEJAY: COMBINING HBV THERAPIES TO REACH A FUNCTIONAL CURE

Bluejay is applying a combination of therapies in-licensed from Novartis with an aim to cure chronic HBV by reducing viral surface antigen in both the liver and blood.

Founder, Chairman and CEO Keting Chu said she had been interested in building a company around HBV assets from Novartis AG (NYSE:NVS; SIX:NOVN) after the pharma exited infectious disease in 2018. A Novartis alum herself, Chu met Novartis Institutes for BioMedical Research’s Jennifer Leeds at a California Life Sciences Institute meeting a few years ago; the connection set the stage for an in-licensing deal. Leeds is executive director and head of BD&L search and evaluation, West Coast and Canada.

Chu said she believed in the assets, knowing that NIBR’s Donald Ganem was involved in their discovery and early development. Ganem, who was VP and head of global infectious diseases research at NIBR in 2011-18, is a professor emeritus of microbiology and immunology at University of California San Francisco, where Chu attended graduate school.

Chu launched Bluejay Therapeutics Inc. in 2019 with exclusive global rights to three of the pharma’s therapies: BJT-778, a mAb against HBV surface antigen (HBsAg); BJT-574, a small molecule HBsAg inhibitor; and a small molecule capsid inhibitor.

Most recently a Lyfe Capital partner, Chu has led multiple start-ups in addition to holding research and executive roles at The Leukemia & Lymphoma Society, Five Prime Therapeutics Inc., Chiron Corp. and Novartis.    Read Full Article